Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications.
The incidence of carbohydrate intolerance and overt diabetes is increased in patients with schizophrenia treated with the newer atypical antipsychotic agents. The precise mechanism for these abnormalities remains obscure. This review examines the potential interaction between atypical antipsychotic medications and several hormones known to influence appetite regulation and carbohydrate metabolism.
Elias
Alan N
AN
The University of California, Irvine Medical Center, Orange, CA 92868, USA. anelias@uci.edu
Hofflich
Heather
H
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000378:metabolism; D054439:Ghrelin / Q000187:drug effects / Q000378:metabolism; D005934:Glucagon / Q000187:drug effects / Q000378:metabolism; D044882:Glucose Metabolism Disorders / Q000139:chemically induced* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D063385:Cannabinoid Receptor Modulators; D054439:Ghrelin; D007328:Insulin; D020738:Leptin; D005934:Glucagon